


BEST USE OF RESOURCES – PRODUCTIVITY & EFFICIENCY

We are driving this measure because

If the Trust fails to identify recurrent Cost and Productivity Improvement Plans (CPIP) and put in place sufficient resources and governance arrangements to drive delivery, then it will not achieve financial sustainability.


YTD CPIP achieved
vs plan target (£53.016m) month



YTD CPIP achieved
vs plan target (£53.016m) cumulative



Schemes identified (forecast) vs target (£53.016m)



Understanding the performance	Actions (SMART)	Risks
M11 delivered actuals of £3.974m against a plan of £6.629m, an under delivery of £2.655m. M11 actuals comprised £2.383m recurrent and £1.591m non-recurrent. YTD actuals are £30.484m against a £46.276m plan, an under delivery of £15.792m. YTD there are £19.771m of recurrent actuals and £10.713m of non-recurrent actuals. M11 Actuals benefitted from £1.418m savings achieved as part of the Financial Recovery Plan.	The Trust is continuing to mitigate the underperformance of CPIP for 25/26 whilst also progressing with the identification and maturing of schemes for 26/27. This is taking place alongside the Trusts Financial recovery Plan for 25/26 with heightened focus on Q4 performance to mitigate the forecast deficit.	Delivery of the 25/26 target is challenging. Work is continuing to develop existing schemes as well as identifying further cost saving and productivity savings via the workshops referenced above to bridge the gap to target (GTT).

BEST USE OF RESOURCES – CAPITAL

We are driving this measure because

The Capital investment programme to replace existing and invest in new additional assets is key to driving improved clinical and financial sustainability. Given the size of capital programme there is a significant risk that the Trust has insufficient funding to support backlog maintenance requirements and much needed equipment replacement.

Trust Capital Position at M11 – Position v Budget

Workstream	Scheme	Annual Budget	YTD Budget	YTD Actual	YTD Variance
Strategic	RAAC A Block Link KTC	296,850.20	296,850.20	275,399.59	-21,450.61
P&W	P&W Backlog Maintenance	1,674,371.14	738,371.14	418,465.42	-319,905.72
Strategic	National Funding Fire Scheme	3,000,000.00	2,993,737.79	1,192,023.02	-1,801,714.77
Strategic	National Diagnostics - Cath lab	0.00	0.00	30,787.85	30,787.85
Strategic	LINACS WRH Replacement	3,321,000.00	3,321,000.00	19,627.86	-3,301,372.14
Digital	LIMS Pathology	370,000.00	370,000.00	396,563.77	26,563.77
Other	Lease Modifications	0.00	0.00	1,379,535.13	1,379,535.13
Strategic	Internally funded Fire Scheme	2,600,000.00	2,600,000.00	2,424,912.82	-175,087.18
Other	IFRIC 12 and other contingency	2,750,501.33	2,695,071.72	1,770,340.91	-924,730.81
Digital	Frontline Digital	0.00	0.00	-34,226.27	-34,226.27
Digital	Externally Funded Constitutional Schemes	1,091,000.00	0.00	123,849.29	123,849.29
Equipment	Externally Funded Constitutional Schemes	250,000.00	140,000.00	69,063.66	-70,936.34
P&W	Externally Funded Constitutional Schemes	0.00	0.00	1,133.04	1,133.04
Strategic	Externally Funded Constitutional Schemes	5,999,000.00	1,671,000.00	338,871.35	-1,332,128.65
Digital	Externally Funded	198,000.00	0.00	0.00	0.00
P&W	Externally Funded	900,000.00	0.00	0.00	0.00
Equipment	Equipment Schemes	381,655.94	367,351.94	850,578.37	483,226.43
Equipment	Equipment Contingency	748,696.00	0.00	0.00	0.00
Other	Donated Equipment Schemes	536,777.02	318,867.62	421,025.07	33,157.45
Digital	Digital rev to cap transfer	0.00	0.00	1,342,902.63	1,342,902.63
Digital	Cyber Improvement PDC	39,000.00	0.00	32,500.00	32,500.00
Other	Contingency Scheme	0.00	0.00	41,689.15	41,689.15
Strategic	Children's Estate Development	0.00	0.00	78,573.20	78,573.20
Strategic	Cath lab feasibility	0.00	0.00	1,010.09	1,010.09
Digital	CAP2425 Cardiac PACS	300,000.00	300,000.00	189,300.04	-110,699.96
Digital	Additional Digital Schemes	0.00	0.00	140,931.92	140,931.92
Strategic	Acute Service Review	4,001,855.00	154,287.62	24,855.75	-129,431.87
Other	2526 LSE WRH Car park	259,000.00	259,000.00	0.00	-259,000.00
Other	2526 LSE Fleet vehicles	345,000.00	345,000.00	16,106.79	-328,893.21
Total		29,511,129.01	16,605,960.41	11,752,234.04	-4,922,726.37

Strategic - (£6.65m) Variance

Waiting on updated cashflows for Fire scheme as spend to date is significantly below what was initially expected, assurance provided that the scheme will be fully spent by year end. Linacs scheme has also yet to be delivered and is expected in M12.

Other (£169k) Variance

No budget for the CHEC building lease re-measurement. Offset by Fleet vehicles leases not included in spend yet and the IFRIC 12 additions being lower than expected.

P&W - (£37k) Variance

VAT credit on the UEC scheme.

Digital £1,522k Variance

Laptops and other items purchased in year have been recharged to capital after review, not originally in annual plan.

Equipment - £412k Variance

Equipment schemes on plan and target for full spend this year.

The Capital finance team will continue to chase resolution of outstanding items, to ensure they can be completed.

Understanding the performance	Actions (SMART)	Risks
The Year-to-date capital spend at M11 is £11.75m, the majority of which is spend on the ALX Fire scheme (£3.6m) IFRIC 12/PFI lifecycle replacements (£1.8m) additional digital schemes including laptop purchased in year (£1.1m) and the CHEC Lease Remeasurement (£1.38m) At M11 capital spend is underspent by £4,923k compared to the plan YTD.	The Capital finance team will continue to work with the workstream leads to ensure all approved capital schemes are completed within the Trust CRL.	There is a significant risk that the Trust has insufficient funding to support backlog maintenance requirements, much needed replacement schemes and a contingency for any unforeseen events.

BEST USE OF RESOURCES – CASH

We are driving this measure because

Daily monitoring of the Trust cash position to ensure there are sufficient funds to cover employee costs and the payment of Trust suppliers as per the BPPC guidance.

The Trust cash position at the end of Month 11 was £10.143m which is higher than forecast, due to the early amount drawn down of Capital PDC of £5.2m which was scheduled for March. The Trust had initially applied for £15.5m of Provider Revenue Support for March; however following discussions with the ICB and the Regional finance leads, and the application has been withdrawn. Instead, the Trust will receive Deficit Support Funding (DSF) of £11.8m for Q4. The remaining cash shortfall of £3.7m will be managed through tighter control of our supplier payments to ensure sufficient cash is available to cover the payroll c£40m.

The cash position is monitored daily, which includes the agreed debtors and creditors to ensure payroll costs are prioritised.

Understanding the performance	Actions (SMART)	Risks
The Trust cash position at the end of Month 11 was £10.143m which is higher than forecast, due to the early amount drawn down of Capital PDC of £5.2m which was scheduled for March. The cash position is monitored daily, which includes the agreed debtors and creditors to ensure payroll costs are prioritised.	The Trust had initially applied for £15.5m of Provider Revenue Support for March; however following discussions with the ICB and the Regional finance leads, and the application has been withdrawn. Instead the Trust will receive Deficit Support Funding (DSF) of £11.8m for Q4. The remaining cash shortfall of £3.7m will be managed through tighter control of our supplier payments to ensure sufficient cash is available to cover the payroll c£40m.	The timing of the mitigation schemes may differ to the planned cash forecast or not come to fruition. Suppliers may put the Trust on stop if payments terms are not adhered too, which in turn will jeopardise supplies and services to the Trust for patient care. As noted above, the Trust will need to manage the shortfall of £3.7m (difference between cash application and deficit support funding) through creditor payment runs, which could disrupt the supplies and services to the Trust.

Worcestershire Acute Hospitals NHS Trust
Trust Key Performance Indicators (KPIs) - up to Feb-26 data

Performance Against Target (Status)
Meeting Target
Not Meeting Target
Activity Performance Only
Over 5% above Target
5% above to 2% below Target
More than 2% below Target to 5% below Target
Over 5% below Target

Table with 3 columns: Type, Item, Description. It lists various performance indicators and their corresponding status icons and descriptions.

Example
Data Quality Assurance Questions
S - Sign Off and Validation
T - Timely & Complete
A - Audit & Accuracy
R - Robust Systems & Data Capture

Main KPI table with columns: Quality of care, access and outcomes, Responsible Director, Standard, Apr-25, May-25, Jun-25, Jul-25, Aug-25, Sep-25, Oct-25, Nov-25, Dec-25, Jan-26, Feb-26. Rows include Cancer, Urgent and emergency care, Elective care, Maternity, and Outpatient transformation.

Summary table with columns: Latest Month, Latest Available Monthly Position, SPCs, DQ Mark. It provides a high-level overview of the performance data, including year-to-date percentages and trend indicators.

Safe, high quality care	Maternity - Women who were smokers at time of delivery (SATOD)	Chief Nursing Officer	-	3.9%	6.5%	5.7%	4.4%	5.0%	4.4%	4.1%	4.0%	3.2%	3.5%	2.1%	8	388	4.3%							
	Bed Occupancy - Adult General & Acute Wards	Chief Operating Officer	<92%	96%	96%	95%	94%	93%	94%	94.5%	94.6%	93.4%	96.3%	95.5%	790	828	95%		92%	Jan-26 Q3 (25/2)				
	Mixed Sex Accommodation Breaches	Chief Nursing Officer	0	55	62	46	60	52	55	53	56	61	58	38			596		5,015	Jan-26 Q3 (25/2)				
	ALoS - General & Acute Adult Emergency Inpatients	Chief Operating Officer	4.5	7.3	7.4	7.3	7.0	6.7	7.1	7.24	6.92	6.58	6.88	7.52	20728	2755	7.1		4.4	Feb to Jan				
	ALoS – General & Acute Elective Inpatients	Chief Operating Officer	2.5	3.1	3.1	3.3	2.5	3.6	3.4	3.16	3.7	3.63	3.29	3.84	1605	418	3.3		3.1	Feb to Jan				
	Medically fit for discharge - Acute	Chief Operating Officer	5%	12%	14%	16%	15%	15%	12%	12%	12%	11%	14%	16%	127	796	13.0%		23.1%	Dec				
	Emergency readmissions within 30 days of discharge (G&A only)	Chief Medical Officer	5%	4.65%	4.87%	4.62%	4.73%	4.67%	4.69%	4.44%	4.84%	4.86%	5.01%	4.84%	551	1373	4.7%		7.5%	Jan to Dec				
	Mortality SHMI - Rolling 12 months *NHSE NOF*	Chief Medical Officer	100	110.71	110.55	111.77	111.51	111.51	112.19									As expected						
	MRSA Bacteraemia *NHSE NOF*	Chief Nursing Officer	0	1	0	0	1	1	2	0	0	0	0	0			5							
	Number of external reportable >AD+1 clostridium difficile cases *NHSE NOF*	Chief Nursing Officer	78	4	8	14	10	11	14	12	8	13	5	10			118							
	Number of falls with moderate harm and above	Chief Nursing Officer		5	4	4	4	4	4	1	1	1	2	4			36							
	VTE Risk Assessments	Chief Medical Officer	95%	91.07	90.52	90.54	91.37	91.63	92.50%	92.95%	91.34%	92.14%	92.91%	93.64%	10,534	11,250	92%							
	Stroke: 80% of patients spend 90% of time on the Stroke ward	Chief Medical Officer	80%	47.5%	57.1%	57.9%	65.2%	67.3%	77.8%	62.5%	68.7%	66.7%	79.0%	68.3%	43	63	63%							
	Complaints resolved within policy timeframe	Chief Nursing Officer	85%	64%	69%	78%	54%	79%	67%	63%	65%	64%	56%	64%	40	62	65%							
	Friends and Family Test Score: Recommended/Experience by Patients (A&E)	Chief Nursing Officer	95%	84%	81%	85%	84%	80%	80%	82%	81%	82%	84%	93%	1988	2136	83%		78%	Jan-26				
	Friends and Family Test Score: Recommended/Experience by Patients (Acute Inpatients)	Chief Nursing Officer	95%	96%	96%	96%	96%	95%	96%	97%	95%	95%	96%	94%	3861	4104	96%		95%					
	Friends and Family Test Score: Recommended/Experience by Patients (Maternity)	Chief Nursing Officer	95%	98%	93%	96%	97%	96%	97%	94%	94%	95%	97%	95%	153	162	96%		92%					
	Friends and Family Test: Response rate (A&E)	Chief Nursing Officer	20%	13%	25%	16%	24%	19%	18%	16%	15%	12%	17%	16%	2136	13453	18%							
	Friends and Family Test: Response rate (Acute inpatients)	Chief Nursing Officer	30%	32%	36%	35%	36%	31%	31%	38%	33%	32%	23%	37%	4104	11160	35%							
	Friends and Family Test: Response rate (Maternity)	Chief Nursing Officer	30%	26%	21%	11%	23%	18%	14%	14%	17%	10%	11%	18%	162	898	17.0%							

Wells-Jo
13/04/2026 16:23:02

People		Responsible Director	Standard	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26
Looking after our people	Agency (agency spend as a % of total pay bill)	Chief People Officer	6%	6.6%	4.8%	5.3%	4.6%	3.2%	4.6%	3.6%	4.1%	2.9%	3.4%	5.5%
	Appraisals - Non-medical	Chief People Officer	90%	83.0%	84.0%	84.0%	83.0%	82.0%	82.0%	83.0%	84.0%	85.0%	84.0%	83.0%
	Appraisals - Medical	Chief People Officer	90%	96.0%	96.0%	94.0%	94.0%	94.0%	93.0%	96.0%	95.0%	96.0%	94.0%	94.0%
	Mandatory Training	Chief People Officer	90%	90.0%	90.0%	91.0%	91.0%	90.0%	91.0%	90.0%	90.0%	90.0%	90.0%	90.0%
	Overall Sickness	Chief People Officer	4.5%	5.1%	4.8%	4.7%	5.2%	5.5%	5.5%	5.7%	5.6%	5.9%	5.8%	5.7%
	Staff Turnover Rate (Rolling 12 months)	Chief People Officer	12%	9.0%	8.9%	8.6%	8.4%	8.1%	8.0%	7.9%	8.1%	7.7%	7.5%	7.5%
	Vacancy Rate	Chief People Officer	8%	7.2%	7.4%	7.3%	7.6%	7.1%	6.8%	6.2%	6.6%	6.6%	6.9%	6.7%

Latest Month		Year to Date	Latest Available Monthly Position			SPCs		DQ Mark
Numerator	Denominator		Latest month v benchmark	National or Regional		Pass/Fail	Trend Variation	
		4.4%						
5,399	6,533	83.4%						
594	632	94.7%						
80,910	90,402	90.3%						
11,402	201,493	5.4%						
487	6,481	8.1%						
518	7,201	7.0%						



Finance and Use of Resources		Responsible Director	Standard	Apr-25	May-25	Jun-25	Jul-25	Aug-25	Sep-25	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26
Finance	I&E - Surplus/(Deficit) (£k)	Chief Finance Officer	≥0	-£3,631	-£3,063	-£2,149	-£339	-£2,292	-£745	£2,773	-£4,741	-£2,037	-£6,266	£3,417
	I&E - Margin (%)	Chief Finance Officer	≥0%	-5.7%	-4.8%	-3.3%	-0.5%	-3.6%	-1.1%	-5.7%	-7.2%	-3.0%	-9.9%	4.8%
	I&E - Variance from plan (£k)	Chief Finance Officer	≥0	-£221	-£68	£141	£199	-£40	£23	-£12	-£6,148	-£3,559	-£8,366	£1,725
	I&E - Variance from Plan (%)	Chief Finance Officer	≥0%	6.0%	2.0%	-6.0%	-38.0%	2.0%	-3.0%	0.0%	-437.0%	-234.0%	-398.0%	102.0%
	CPIP - Variance from plan (£k)	Chief Finance Officer	≥0	-£593	£147	-£152	-£563	-£2,833	-£489	£2,346	-£4,574	-£4,190	-£4,411	-£2,654
	Agency - expenditure (£k)	Chief Finance Officer	N/A	-£2,294	-£1,983	-£2,215	-£1,988	-£1,275	-£1,404	-£1,501	-£1,825	-£1,234	-£1,460	-£1,186
	Agency - expenditure as % of total pay	Chief Finance Officer	N/A	5.5%	4.8%	5.3%	4.6%	3.2%	3.4%	3.6%	4.2%	2.9%	3.4%	2.8%
	Capital - Variance to plan (£k)	Chief Finance Officer	≥0	£664	£328	-£378	£1,420	£11	£1,489	-£1,204	-£2,069	-£2,122	-£1,544	-£991
	Cash - Balance at end of month (£m)	Chief Finance Officer	As Per Plan	£21.887m	£21.443m	£17.673m	£18.698m	£15.859m	£6.160m	£6.39m	£4.638m	£4.478m	£10.678m	£10.143m
	BPPC - Invoices paid <30 days (% value £k)	Chief Finance Officer	≥95%	92%	94%	94%	92%	90%	91%	90%	98%	90%	82%	75%
	BPPC - Invoices paid <30 days (% volume)	Chief Finance Officer	≥95%	91%	94%	91%	82%	90%	92%	94%	96%	89%	83%	71%

Latest Month		Year to Date	Latest Available Monthly Position			SPCs		DQ Mark
Numerator	Denominator		Latest month v benchmark	National or Regional		Pass/Fail	Trend Variation	
		-£19,072						
		-5.7%						
		-£16,326						
		6.0%						
		-£15,877						
		-£18,365						
		4.0%						
		-£4,396						
		-						
		-						
		-						

Wells-Jo
13/04/2026 16:23:02

WORCESTERSHIRE ACUTE HOSPITALS NHS TRUST COVERING REPORT

Report to:	Public Board
Date of Meeting:	14/04/2026
Title of Report:	Patient and Public Forum bi-annual report
Lead Executive Director:	Chief Nursing Officer
Author:	Rosemary Smart, Chair of the Patient and Public Forum, Kimara Sharpe, Vice Chair, members of the Patient and Public Forum (PPF) and Anna Sterckx, Head of Patient, Carer and Public Engagement.
Reporting Route:	Quality Governance Committee
Appendices included with this report:	Patient and Public Forum report PPF Work Plan
Purpose of report:	☒ Assurance ☐ Approval ☒ Information
Brief Description of Report Purpose	
The overall purpose of the Patient and Public Forum (PPF) is to ensure that the voices of patients, relatives, carers and the public are heard by the Trust and acted on in order to achieve the highest quality patient centred care. The PPF Terms of Reference specifies that the PPF Chair and Chief Nursing Officer will provide a twice-yearly report to the Trust Board outlining the business of the Forum and progress made against development and delivery of the Patient Voice and Involvement Strategy.	
Recommended Actions required by Board or Committee	
To NOTE the continued progress and ongoing development of the Patient and Public Forum in terms of active participation and partnership with the Trust, external engagement and community engagement, in particular the Hearing Loop report and standard of Outpatient letters.	
Executive Director Opinion¹	
As the Chief Nurse, I am incredibly grateful for the work and commitment of our PPF. The depth and breadth of work is far reaching and incredibly valuable on all levels. I am keen to work more closely with the forum to support the cultural changes we are focused on delivering.	

¹ Executive director opinion must be included and approved by the director concerned prior to issue, except when the director has given their consent for the report to be released.